TVRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tvardi Therapeutics Inc (TVRD) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock lacks positive momentum, has weak financial performance, and faces significant risks as highlighted by analysts. The absence of recent positive news or catalysts further supports a hold recommendation.
The MACD is slightly positive at 0.0304 but contracting, RSI is neutral at 39.203, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 2.914, with resistance at 3.426. Overall, the technical indicators suggest a lack of strong upward momentum.
Lucid Capital upgraded the stock to Buy in February 2026, citing undervaluation and potential for its assets to drive growth. The upcoming Phase 1 TTI-109 readout in Q2 2026 could provide insights into the company's drug pipeline.
Barclays downgraded the stock to Underweight in April 2026, citing funding overhang and delays in the Phase 2 REVERT study. Analysts have also lowered price targets, reflecting a cautious outlook. The stock has an 80% chance of declining in the short term based on candlestick analysis.
In Q4 2025, the company reported zero revenue growth YoY, a net income loss of -$7.28M (down -42.75% YoY), and a significant EPS decline of -84.41% YoY. These metrics indicate weak financial health and lack of profitability.
Analysts have a mixed to negative view. Barclays downgraded the stock to Underweight with a price target of $3, citing risks and funding concerns. Piper Sandler maintained a Neutral rating but lowered the price target to $3. Lucid Capital remains optimistic with a Buy rating and a $6 price target, citing undervaluation and potential catalysts.
